Return of Pharmaceutical Plant Pharma Start: Acino Resumes Production

The Pharma Start pharmaceutical plant, which operates under the Acino umbrella, has officially completed the restoration of its operations after enduring multiple Russian missile strikes during the summer of 2025. The company's press service, NV Business, reported that this recovery was made possible due to the relentless efforts of the Acino team, who have been working diligently on this process for the past nine months.

During this period, the plant underwent extensive reconstruction of its production areas and modernization of its equipment, significantly enhancing production efficiency. Acino invested approximately 500 million hryvnias into these efforts, demonstrating a serious commitment to supporting the pharmaceutical industry in Ukraine, even amidst the ongoing war.

Currently, a portion of the pharmaceutical products manufactured at the plant is already being supplied to pharmacy networks, indicating a return to normal operations. The press service of Acino noted that the company plans to achieve full production recovery by the beginning of the second quarter of 2026, marking an important step towards meeting the medical needs of the population.

It is worth recalling that in mid-2025, the Pharma Start plant suffered five Russian missile attacks that caused significant damage to its production facilities. After the first strike, the plant managed to resume its activities in July 2025; however, it soon fell victim to further missile strikes, complicating the recovery process.

Pharma Start is one of the largest pharmaceutical manufacturers in Ukraine, capable of producing up to 2 billion tablets and capsules annually. The plant specializes in the production of medications for treating a variety of diseases, including neurological, psychiatric, and cardiovascular conditions. This specialization makes it a crucial player in the medical products market in Ukraine, particularly in light of current challenges.

Thus, the restoration of the Pharma Start plant represents not only a significant economic achievement for Acino but also a critical necessity for ensuring the availability of medications for Ukrainians in need of medical assistance. The company continues to work on improving production processes and ensuring high-quality products, despite the difficult circumstances in which it operates.